Lumos Pharma Inc expected to post a loss of 87  cents a share - Earnings Preview

Lumos Pharma

03/05/2021 14:13

* Lumos Pharma Inc  LUMO.OQ   LUMO.O  is expected to show a fall
in quarterly revenue when it reports results on May 5.
* The Austin, Texas-based company is expected to report  a
100.0% decrease in revenue to $0 from $21 thousand a year ago,
according to the mean estimate from 7 analysts, based on
Refinitiv data.​​
​* Refinitiv's mean analyst estimate for Lumos Pharma Inc is for
a loss of 87 cents per share. For the same quarter last year,
the company reported a loss of 14 cents per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 7 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months.​
* Wall Street's median 12-month price target for Lumos Pharma
Inc is $32​, about 61.3% above​ its last closing price
of $12.38. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Dec. 31 2020  -0.86       -0.86      -0.31     Beat    64
 Sep. 30 2020  -0.66       -0.64      0.21      Beat    132.6
 Jun. 30 2020  -0.72       -0.71      -0.65     Beat    8.9​
 Mar. 31 2020  -0.83       -0.82      -0.14     Beat    83
 Dec.          -2.52​      -2.52      -1.98     Beat    21.4​
 31​ 2019​                                              
 Sep. 30 2019  -2.43       -2.43      -2.43     Met     0​
 Jun. 30 2019              -2.61      -2.43     Beat    6.9
 Mar. 31 2019  -2.61       -2.74      -2.43     Beat    11.5
 This summary was machine generated May 3 at 13:13 GMT.  All
figures in US dollars unless otherwise stated